Medicine faculty part of ACTIV-3 trial team lauded by NIH

Sunday, September 27, 2020

A team of Duke Health clinicians that include faculty from the Department of Medicine are working diligently in a collaborative effort to enroll patients in a randomized, controlled trial, testing a novel antibody treatment for COVID-19.

The Duke team’s early success in the ACTIV-3 trial has been recognized by Francis Collins, MD, PhD, director of the National Institutes of Health, and Janet Woodcock, MD, a leader in the federal government's Operation Warp Speed.

The trial is being run out of the Cardiothoracic Surgical Trials Network at Duke. Peter Smith, MD,  professor of surgery, is the primary investigator.

Medicine faculty who are part of the trial include Christina Barkauskas, MD, assistant professor of medicine (Pulmonary, Allergy, and Critical Care Medicine); Thomas Holland, MD, associate professor of medicine (Infectious Diseases); Emily Ko, MD, assistant professor of medicine (General Internal Medicine); Noel Ivey, MD, medical instructor (General Internal Medicine);  John Franzone, MD, medical instructor (General Internal Medicine); and Tatyana Der, MD, medical instructor (General Internal Medicine).

Read more.